Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
79% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. PBYI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PBYI' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6648
N/A
No Debt
F-Score: 3
Z-Score: 8.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -107.88
PBYI's ROE (%) is ranked lower than
84% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. PBYI: -107.88 )
Ranked among companies with meaningful ROE (%) only.
PBYI' s ROE (%) Range Over the Past 10 Years
Min: -141.23  Med: -66.24 Max: -37.64
Current: -107.88
-141.23
-37.64
ROA (%) -95.42
PBYI's ROA (%) is ranked lower than
88% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. PBYI: -95.42 )
Ranked among companies with meaningful ROA (%) only.
PBYI' s ROA (%) Range Over the Past 10 Years
Min: -1700  Med: -89.05 Max: -36.94
Current: -95.42
-1700
-36.94
ROC (Joel Greenblatt) (%) -10677.40
PBYI's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. PBYI: -10677.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PBYI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7408.23  Med: -5178.74 Max: -2978.59
Current: -10677.4
-7408.23
-2978.59
EBITDA Growth (3Y)(%) 53.30
PBYI's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. PBYI: 53.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PBYI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 53.3  Med: 581.85 Max: 728.7
Current: 53.3
53.3
728.7
EPS Growth (3Y)(%) 53.00
PBYI's EPS Growth (3Y)(%) is ranked higher than
92% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. PBYI: 53.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PBYI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 53  Med: 583.35 Max: 729.3
Current: 53
53
729.3
» PBYI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

PBYI Guru Trades in Q2 2015

Jeremy Grantham 1,426,738 sh (New)
Steven Cohen 68,600 sh (+653.85%)
» More
Q3 2015

PBYI Guru Trades in Q3 2015

Jim Simons 162,600 sh (New)
Steven Cohen 554,019 sh (+707.61%)
Jeremy Grantham 1,676,678 sh (+17.52%)
» More
Q4 2015

PBYI Guru Trades in Q4 2015

John Paulson 46,000 sh (New)
Jeremy Grantham 2,899,776 sh (+72.95%)
Steven Cohen 945,478 sh (+70.66%)
Jim Simons Sold Out
» More
Q1 2016

PBYI Guru Trades in Q1 2016

Samuel Isaly 142,000 sh (New)
John Paulson 70,300 sh (+52.83%)
Steven Cohen 1,157,700 sh (+22.45%)
Jeremy Grantham 2,010,801 sh (-30.66%)
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:SHSE:600161, XAMS:GLPG, HKSE:00570, SZSE:002287, XKRX:086900, NAS:TSRO » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc was incorporated in Delaware on April 27, 2007. The Company is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care It is engaged in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Top Ranked Articles about Puma Biotechnology Inc

Sam Isaly Purchases Stake in Puma Biotechnology Company is close to 3-year low in price with no debt
Guru Samuel Isaly purchased a 142,000-share stake in Puma Biotechnology Inc. (NYSE:PBYI) in the first quarter. Read more...

Ratios

vs
industry
vs
history
P/B 7.37
PBYI's P/B is ranked lower than
75% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. PBYI: 7.37 )
Ranked among companies with meaningful P/B only.
PBYI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 62.4
Current: 7.37
0
62.4
EV-to-EBIT -3.95
PBYI's EV-to-EBIT is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. PBYI: -3.95 )
Ranked among companies with meaningful EV-to-EBIT only.
PBYI' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.99  Med: 0.00 Max: 0
Current: -3.95
-5.99
0
EV-to-EBITDA -3.95
PBYI's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. PBYI: -3.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
PBYI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6  Med: 0.00 Max: 0
Current: -3.95
-6
0
Current Ratio 4.87
PBYI's Current Ratio is ranked higher than
53% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. PBYI: 4.87 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.75 Max: 91.42
Current: 4.87
0.67
91.42
Quick Ratio 4.87
PBYI's Quick Ratio is ranked higher than
55% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. PBYI: 4.87 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s Quick Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.75 Max: 91.42
Current: 4.87
0.67
91.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.59
PBYI's Price/Net Cash is ranked lower than
62% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. PBYI: 8.59 )
Ranked among companies with meaningful Price/Net Cash only.
PBYI' s Price/Net Cash Range Over the Past 10 Years
Min: 4.69  Med: 14.73 Max: 60.47
Current: 8.59
4.69
60.47
Price/Net Current Asset Value 8.12
PBYI's Price/Net Current Asset Value is ranked lower than
62% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. PBYI: 8.12 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PBYI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.26  Med: 13.94 Max: 55.83
Current: 8.12
4.26
55.83
Price/Tangible Book 7.34
PBYI's Price/Tangible Book is ranked lower than
67% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. PBYI: 7.34 )
Ranked among companies with meaningful Price/Tangible Book only.
PBYI' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.17  Med: 13.03 Max: 50.75
Current: 7.34
4.17
50.75
Earnings Yield (Greenblatt) (%) -25.14
PBYI's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. PBYI: -25.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PBYI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -48.52  Med: 0.00 Max: 0
Current: -25.14
-48.52
0

More Statistics

EPS (TTM) $ -7.97
Beta0.49
Short Percentage of Float27.39%
52-Week Range $19.74 - 201.49
Shares Outstanding (Mil)32.49

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22 1,165
EPS ($) -7.36 -8.45 11.84
EPS without NRI ($) -7.36 -8.45 11.84
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for PBYI

Headlines

Articles On GuruFocus.com
Sam Isaly Purchases Stake in Puma Biotechnology May 03 2016 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
5 Major Clinical Trial Results Coming Up May 25 2016
PUMA BIOTECHNOLOGY, INC. Financials May 19 2016
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting May 18 2016
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting May 18 2016
Puma Biotechnology to Present at UBS Global Healthcare Conference May 17 2016
Puma Biotechnology to Present at UBS Global Healthcare Conference May 17 2016
XBI Dropped, Markets Fell Due to Retail Sector Concerns May 12 2016
Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus May 11 2016
Puma Biotech reports 1Q loss May 10 2016
Puma Biotech reports 1Q loss May 10 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 10 2016
Puma Biotechnology Reports First Quarter 2016 Financial Results May 10 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report May 10 2016
Puma Biotechnology Reports First Quarter 2016 Financial Results May 10 2016
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More May 06 2016
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings? May 04 2016
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference May 04 2016
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference May 04 2016
Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016 Apr 20 2016
Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016 Apr 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)